SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI: @MyJSCAI
🥸 Nice documents on STEMI and primary PCI: congratulations to authors and @SCAI
😱 Here are few recommendations from the document
👇👇👇
🥸1️⃣ Cardiac Catheterization Laboratory (CCL) Equipment: Ensure availability of plaque modification devices, guide extension devices, and intracoronary imaging tools for effective STEMI management in the catheterization lab.
🥸2️⃣ Use microcatheters to enhance precision by facilitating medication delivery and wire exchange in tortuous coronary arteries during STEMI interventions.
🥸3️⃣ In cases with a large thrombus burden, aspiration catheters—manual or mechanical—should be available to help reduce thrombus and improve reperfusion.
🥸4️⃣ Prioritize team readiness with protocols for rapid CCL activation and streamlined prehospital ECG transmission to cut down on time-to-treatment.
🥸5️⃣ ED Bypass: For stable STEMI patients, bypassing the emergency department can expedite transfer to the CCL and minimize delays in reperfusion.
🥸6️⃣ Opt for transradial access over femoral when possible, as it carries a lower risk of bleeding and vascular complications in STEMI interventions.
#radialfirst
🥸7️⃣ For femoral access cases, use ultrasound and fluoroscopy to ensure accurate access and reduce potential complications at the femoral artery.
🥸8️⃣ Always perform a complete coronary angiogram to assess the full scope of coronary disease, aiding in revascularization strategy for both infarct and non-infarct arteries.
🥸9️⃣ Thrombus Management: Use bail-out aspiration thrombectomy in selected cases with a high thrombus burden to mitigate the risk of no-reflow and distal embolization.
🥸🔟 For the no-reflow phenomenon, intracoronary vasodilators such as adenosine, nitroprusside, and calcium channel blockers are essential to restore microvascular flow.
🥸1️⃣1️⃣ Employ intracoronary imaging (IVUS or OCT) to guide PCI, optimize stent placement, assess stent expansion, and detect complications like malapposition.
🥸1️⃣2️⃣ Newer therapies, like supersaturated oxygen (SSO2) therapy and left ventricular unloading, show potential in reducing myocardial damage by minimizing infarct size during PCI.
🥸1️⃣3️⃣ In cardiogenic shock, implement MCS promptly and perform careful hemodynamic monitoring during and after PCI to improve patient outcomes.
🥸1️⃣4️⃣ Post-fibrinolytic therapy in STEMI, prioritize radial access for rescue PCI to lower bleeding risk and enhance safety.
🥸1️⃣5️⃣ In stent thrombosis cases, utilize intracoronary imaging to assess underlying causes like underexpansion or stent fracture, tailoring interventions based on findings.
🥸1️⃣6️⃣ For STEMI patients with multivessel disease, consider complete revascularization for better outcomes, particularly in stable patients without cardiogenic shock.
🥸1️⃣7️⃣ When treating calcified lesions, use plaque modification tools like atherectomy or intravascular lithotripsy to facilitate stent delivery and expansion.
🥸1️⃣8️⃣ In cases of coronary artery aneurysms, focus on restoring flow using mechanical thrombus management strategies; consider surgical options for large aneurysms.
🥸1️⃣9️⃣ Manage nonatherosclerotic causes of STEMI like SCAD, coronary embolism, and epicardial spasm with tailored approaches; for SCAD, conservative management is preferred for stable patients.
🥸2️⃣0️⃣ For coronary embolism with large thrombus burden, consider PCI with thrombectomy to restore flow, while smaller, distal emboli may be managed conservatively.
🥸2️⃣1️⃣ MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries): In suspected cases, additional imaging such as IVUS or OCT, and cardiac MRI can clarify the underlying cause and guide management.
🥸2️⃣2️⃣ Track quality metrics like door-to-device times and activation delays across the STEMI system to identify areas for improvement and ensure consistent care.
🥸2️⃣3️⃣ False STEMI activations should be minimized through education on ECG interpretation and protocols, as they can lead to unnecessary procedures and resource strain.
🥸2️⃣4️⃣ Intracoronary nitroglycerin is advised during angiography to help identify and treat vasospasm and accurately assess vessel diameter during PCI.
🥸2️⃣5️⃣ In SCAD with TIMI 3 flow, conservative management is advised, reserving PCI for cases with large areas of myocardium at risk or hemodynamic instability.
🥸2️⃣6️⃣ For suspected coronary embolism, evaluate for potential sources such as atrial fibrillation or cardiac thrombus; use thrombectomy devices when necessary for large proximal thrombi.
🥸2️⃣7️⃣ When performing PCI on bifurcation lesions during STEMI, a provisional one-stent strategy is preferred to minimize procedural complexity and potential complications.
🥸2️⃣8️⃣ Ensure CCL team readiness includes protocols for fast prehospital notification, streamlined communication, and an efficient reperfusion timeline to optimize outcomes.
🥸2️⃣9️⃣ Use plaque modification in cases of significant calcification to enhance stent expansion and minimize the risk of post-PCI complications.
🥸3️⃣0️⃣ Continually assess and improve STEMI care protocols by tracking procedural times, outcomes, and complications, aiming for a comprehensive quality improvement approach across the system.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up: @TheLancet
🥸 "The use of MCS should be restricted to certain patients only" ~ @thiele_holger
😱 Summary
👇👇
🥸 1️⃣ Cardiogenic shock still has a high mortality rate, around 40-50%, despite medical advances. For AMI-related cariogenic shock, immediate revascularization is the only proven life-saving treatment.
🥸 2️⃣ Mechanical circulatory support (MCS) devices have become popular after studies showed intraaortic balloon pumps don't reduce mortality in cardiogenic shock.
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy: @NEJM
🥸 There are many parallels between ischemic strokes and ACS Mx
😱Summary and have a nice Sunday
👇👇👇
🥸 1️⃣ Intravenous thrombolytic agents, such as alteplase, are recommended for eligible patients to be administered within 4.5 hours after the onset of an acute ischemic stroke to maximize the chances of recovery.
🥸 2️⃣ Tenecteplase, a genetically modified form of human tissue plasminogen activator, has been shown to be noninferior to alteplase for the treatment of ischemic stroke.
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary InterventionA Systematic Review and Patient-Level Meta-Analysis: @JAMACardio
🥸 Good morning: more on SAPT monotherapy vs DAPT
😱Summary
👇👇👇
1.🥸 Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard post-PCI to minimize ischemic events, but it increases bleeding risk. Emerging studies prompt a reassessment.
😱 Mainly, in high risk groups: older adults.
2. 🥸 Short DAPT durations followed by P2Y12 inhibitor monotherapy have shown promising reductions in bleeding but raised concerns re ischemic risks in high-risk patients.
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials: @CircAHA
🥸wow: more on left main+diabetes: PCI vs CABG!
😱 Summary
👇👇👇
1/ 🥸 Left main coronary artery disease and diabetes are associated with substantial cardiovascular morbidity and mortality.
2/ 🥸 Yet, long-term outcomes for patients with left main disease and diabetes undergoing PCI compared with CABG remain unclear.
Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society: @CircAHA
🥸Great work: @AHA_Research @AHA_AcuteCVCare
😱Let's summarize: Happy Sunday :)
👇👇👇
1/🥸 Cardiac Arrest Prevalence: Over 600,000 individuals in the US experience cardiac arrest annually.
😱This is a significant public health problem.
2/ 🥸 Worldwide Incidence: Globally, cardiac arrest occurs in 30 to 97 individuals per 100,000 population.
Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.
2/CARDIA-SSBP:
🥸The decline in SBP with a low-sodium diet was independent of hypertension status and anti-hypertensive medication use, consistent across subgroups, and did not result in excess adverse
3/ CRHCP:
🥸Intensive BP lowering (target BP < 130/80 mm Hg) significantly reduced risk of all-cause dementia among patients with hypertension, supporting the use of intensive hypertension treatment to reduce the burden of dementia.